|
Name |
Chaetoglobosin D
|
Molecular Formula | C32H36N2O5 | |
IUPAC Name* |
(1R,3E,6R,7E,9S,11E,13R,14S,16S,17R,18S)-6,14-dihydroxy-18-(1H-indol-3-ylmethyl)-7,9,16-trimethyl-15-methylidene-19-azatricyclo[11.7.0.01,17]icosa-3,7,11-triene-2,5,20-trione
|
|
SMILES |
C[C@H]\1C/C=C/[C@H]2[C@@H](C(=C)[C@H]([C@@H]3[C@@]2(C(=O)/C=C/C(=O)[C@@H](/C(=C1)/C)O)C(=O)N[C@H]3CC4=CNC5=CC=CC=C54)C)O
|
|
InChI |
InChI=1S/C32H36N2O5/c1-17-8-7-10-23-30(38)20(4)19(3)28-25(15-21-16-33-24-11-6-5-9-22(21)24)34-31(39)32(23,28)27(36)13-12-26(35)29(37)18(2)14-17/h5-7,9-14,16-17,19,23,25,28-30,33,37-38H,4,8,15H2,1-3H3,(H,34,39)/b10-7+,13-12+,18-14+/t17-,19+,23-,25-,28-,29+,30+,32+/m0/s1
|
|
InChIKey |
FTBNYQWFSWKCKW-WHHLLCSSSA-N
|
|
Synonyms |
Chaetoglobosin D; CHEBI:68807; Cheatoglobosin D; 55945-73-8; SCHEMBL33530; CHEMBL520561; FTBNYQWFSWKCKW-WHHLLCSSSA-; Q27137190; (1R,3E,6R,7E,9S,11E,13R,14S,16S,17R,18S)-6,14-dihydroxy-18-(1H-indol-3-ylmethyl)-7,9,16-trimethyl-15-methylidene-19-azatricyclo[11.7.0.01,17]icosa-3,7,11-triene-2,5,20-trione; (3S,3aR,4S,6S,6aR,7E,10S,11E,13R,15E,17aR)-6,13-dihydroxy-3-(1H-indol-3-ylmethyl)-4,10,12-trimethyl-5-methylidene-2,3,3a,4,5,6,6a,9,10,13-decahydro-1H-cyclotrideca[d]isoindole-1,14,17-trione
|
|
CAS | NA | |
PubChem CID | 23259920 | |
ChEMBL ID | CHEMBL520561 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 528.6 | ALogp: | 3.2 |
HBD: | 4 | HBA: | 5 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 120.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 39 | QED Weighted: | 0.342 |
Caco-2 Permeability: | -5.009 | MDCK Permeability: | 0.00001320 |
Pgp-inhibitor: | 0.885 | Pgp-substrate: | 0.965 |
Human Intestinal Absorption (HIA): | 0.083 | 20% Bioavailability (F20%): | 0.204 |
30% Bioavailability (F30%): | 0.003 |
Blood-Brain-Barrier Penetration (BBB): | 0.191 | Plasma Protein Binding (PPB): | 91.06% |
Volume Distribution (VD): | 0.68 | Fu: | 4.28% |
CYP1A2-inhibitor: | 0.065 | CYP1A2-substrate: | 0.195 |
CYP2C19-inhibitor: | 0.501 | CYP2C19-substrate: | 0.348 |
CYP2C9-inhibitor: | 0.521 | CYP2C9-substrate: | 0.344 |
CYP2D6-inhibitor: | 0.069 | CYP2D6-substrate: | 0.124 |
CYP3A4-inhibitor: | 0.935 | CYP3A4-substrate: | 0.246 |
Clearance (CL): | 6.256 | Half-life (T1/2): | 0.267 |
hERG Blockers: | 0.065 | Human Hepatotoxicity (H-HT): | 0.819 |
Drug-inuced Liver Injury (DILI): | 0.528 | AMES Toxicity: | 0.074 |
Rat Oral Acute Toxicity: | 0.908 | Maximum Recommended Daily Dose: | 0.96 |
Skin Sensitization: | 0.151 | Carcinogencity: | 0.127 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.007 |
Respiratory Toxicity: | 0.98 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002953 | 0.815 | D01TSI | 0.255 | ||||
ENC002120 | 0.802 | D0W7WC | 0.248 | ||||
ENC002681 | 0.800 | D02DMQ | 0.248 | ||||
ENC003226 | 0.785 | D0BV3J | 0.247 | ||||
ENC004473 | 0.779 | D0SP3D | 0.242 | ||||
ENC004447 | 0.742 | D09NNH | 0.242 | ||||
ENC002682 | 0.728 | D0V3ZA | 0.242 | ||||
ENC002442 | 0.701 | D05EJG | 0.240 | ||||
ENC002679 | 0.685 | D02XIY | 0.233 | ||||
ENC002678 | 0.662 | D09ZIO | 0.225 |